TD Asset Management Inc Sells 9,679 Shares of Revvity Inc. $RVTY

TD Asset Management Inc cut its holdings in shares of Revvity Inc. (NYSE:RVTY) by 9.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 89,011 shares of the company’s stock after selling 9,679 shares during the quarter. TD Asset Management Inc owned approximately 0.08% of Revvity worth $7,802,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. CYBER HORNET ETFs LLC bought a new position in Revvity during the second quarter valued at approximately $32,000. MUFG Securities EMEA plc acquired a new stake in shares of Revvity in the 2nd quarter worth $34,000. Headlands Technologies LLC acquired a new position in shares of Revvity in the 2nd quarter valued at $49,000. Smartleaf Asset Management LLC grew its position in shares of Revvity by 56.8% during the 3rd quarter. Smartleaf Asset Management LLC now owns 690 shares of the company’s stock valued at $58,000 after acquiring an additional 250 shares during the period. Finally, Quent Capital LLC acquired a new position in shares of Revvity during the 3rd quarter worth approximately $71,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Price Performance

Shares of NYSE RVTY opened at $95.65 on Tuesday. The stock has a 50 day moving average of $103.26 and a two-hundred day moving average of $96.55. Revvity Inc. has a twelve month low of $81.36 and a twelve month high of $120.39. The stock has a market cap of $10.69 billion, a P/E ratio of 45.99, a P/E/G ratio of 2.09 and a beta of 1.10. The company has a current ratio of 1.68, a quick ratio of 1.40 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY) last released its earnings results on Monday, February 2nd. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.55 by $0.15. The company had revenue of $772.06 million during the quarter, compared to analysts’ expectations of $759.81 million. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The business’s revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the business earned $1.42 EPS. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. On average, research analysts forecast that Revvity Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 8th. Shareholders of record on Friday, April 17th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date is Friday, April 17th. Revvity’s dividend payout ratio (DPR) is 13.46%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on RVTY shares. TD Cowen restated a “hold” rating on shares of Revvity in a research report on Tuesday, February 3rd. The Goldman Sachs Group assumed coverage on shares of Revvity in a research report on Tuesday, December 9th. They set a “neutral” rating and a $105.00 price objective for the company. Wall Street Zen upgraded shares of Revvity from a “hold” rating to a “buy” rating in a research note on Saturday. Barclays upped their price target on Revvity from $115.00 to $118.00 and gave the stock an “overweight” rating in a report on Tuesday, February 3rd. Finally, JPMorgan Chase & Co. boosted their price objective on Revvity from $100.00 to $105.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 3rd. Five investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $113.67.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.